Coadministration of a cabozantinib capsule formulation with a strong CYP3A4 inhibitor increased the exposure of cabozantinib, which may increase the risk of exposure-related adverse reactions. Avoid coadministration of Cabozantinib with strong CYP3A4 inhibitors. Reduce the dosage of Cabozantinib if coadministration with strong CYP3A4 inhibitors cannot be avoided. Avoid grapefruit or grapefruit juice which may also increase exposure of cabozantinib.
Coadministration of a cabozantinib capsule formulation with a strong CYP3A4 inducer decreased the exposure of cabozantinib, which may reduce efficacy. Avoid coadministration of Cabozantinib with strong CYP3A4 inducers. Increase the dosage of Cabozantinib if coadministration with strong CYP3A4 inducers cannot be avoided. Avoid St. John’s wort which may also decrease exposure of cabozantinib.
from FDA,2023.09
Cabozantinib is a multi-kinase inhibitor that is often used in combination with other drugs in clinical treatment, but its interaction with other drugs is a cause for concern.What ···【more】
Article source:Lucius LaosRelease date:2025-02-26Recommended:83
Cabozantinib is a multi-targeted tyrosine kinase inhibitor that has been widely used in the treatment of a variety of tumors in clinical practice. However, its interactions with ot···【more】
Article source:Lucius LaosRelease date:2025-02-25Recommended:91
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: